Join Now

Category Archives: BioUtah News

E&I Ski Day 2025 Recap

By Natalie Themm | Published March 20, 2025

E&I Ski Day 2025 Recap

| Comments Off on E&I Ski Day 2025 Recap

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

By Natalie Themm | Published March 20, 2025

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

| Tagged | Comments Off on Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

By admin | Published March 13, 2025

Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. This prestigious award provides Halia with a fully sponsored […]

| Comments Off on Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

By Natalie Themm | Published March 13, 2025

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

| Comments Off on The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

First Patient Enrolled in Merit Medical’s PREEMIE Study

By Natalie Themm | Published March 13, 2025

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

| Tagged | Comments Off on First Patient Enrolled in Merit Medical’s PREEMIE Study

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

By Natalie Themm | Published March 13, 2025

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

| Tagged | Comments Off on iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

Altitude Lab Demo Day

By Natalie Themm | Published February 20, 2025

As part of BioHive week, Altitude Lab hosted its annual Demo Day.

| Tagged | Comments Off on Altitude Lab Demo Day

Steve Pacelli Appointed CEO of Epitel, Inc.

By Natalie Themm | Published February 13, 2025

Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth

| Tagged | Comments Off on Steve Pacelli Appointed CEO of Epitel, Inc.

Sera Prognostics Announces Pricing of $50 Million Public Offering

By Natalie Themm | Published February 13, 2025

Sera Prognostics Announces Pricing of $50 Million Public Offering

| Tagged | Comments Off on Sera Prognostics Announces Pricing of $50 Million Public Offering

The Teva Turnaround: Steering a Company Comeback

By Natalie Themm | Published February 13, 2025

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.

| Tagged | Comments Off on The Teva Turnaround: Steering a Company Comeback

Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

By Natalie Themm | Published February 13, 2025

Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

| Tagged | Comments Off on Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

By Natalie Themm | Published February 13, 2025

bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

| Tagged | Comments Off on bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

A Special Thanks To Our Legacy and Platinum Elite Members